Navigation Links
Tolera Therapeutics Granted Orphan Drug Designation for Treatment of Type 1 diabetes mellitus
Date:6/22/2010

KALAMAZOO, Mich., June 22 /PRNewswire/ -- Tolera Therapeutics, Inc., was granted orphan drug status by the United States Food and Drug Administration (FDA) for TOL101 (anti-TCR murine monoclonal antibody, type IgM), for treatment of recent onset immune-mediated Type 1 diabetes mellitus (T1DM).  Designation is granted for treatment of patients sixteen years of age and younger with immune-mediated T1DM and preserved pancreatic beta-cell function, commonly referred to as juvenile diabetes.

"We are pleased with this designation," commented John J. Puisis, President and CEO of Tolera.  "Clinicians and patients need an effective and safe means to modulate the immune system, particularly for juvenile diabetes patients.  Current treatments and industry pipelines offer very few solutions to advance patient care, leaving these young patients with a deteriorating disease condition.  Thus far, these treatments can only offset disease symptoms, or slow disease progression, but at the cost of potentially serious side effects. We believe we are developing a therapy that will prove to be both safe and effective, thus providing the patient with a much better treatment outcome."

The Orphan Drug Act was enacted to allow the FDA to grant a product special orphan status when it is intended to treat rare diseases or conditions -- those that affect fewer than 200,000 people annually in the United States. This special designation waives governmental filing fees, provides the drug sponsor with tax credits related to development expenses, as well as other support.  In addition, orphan drug designation creates the opportunity for the sponsor to apply for orphan drug grant money from the U.S. government to help support clinical trials.  As an agent with the potential to aid patients with a severe condition, TOL101 meets the stringent FDA requirements for orphan drug designation.  This designation will facilitate TOL101's entry into the clinic, where relatively few new therapies have emerged over the last ten years, and there is a growing need for safer, more targeted immunological therapeutic approaches.

About Tolera Therapeutics:  Tolera Therapeutics is a Kalamazoo, Michigan based biotechnology company and a spin-off of the Cleveland Clinic Foundation.  Primary investors in the company include Southwest Michigan First Life Sciences Fund, Triathlon Medical Venture Partners, Hopen Therapeutics and the Michigan Economic Development Corporation.  Building upon research done at the University of Kentucky and the Cleveland Clinic, Tolera Therapeutics is developing and commercializing therapies for the immune modulation market with the goal of addressing unmet medical needs with safer, more targeted solutions to reduce the risk of serious and toxic side effects often associated with immunotherapy.  The company is focusing on commercializing therapeutic monoclonal antibody technology for the transplantation and autoimmune markets.  Additional information concerning the company and its technology can be found on its website www.tolera.com.  


'/>"/>
SOURCE Tolera Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
3. Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome
4. Study Shows VAPRISOL(R) is Effective in Increasing Serum Sodium Levels and Well-Tolerated in Patients With Euvolemic or Hypervolemic Hyponatremia
5. IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients
6. IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
7. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
8. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
9. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
10. Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
11. Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... December 7, 2016 According to ... titled , Global Market Study on Multiplex Detection Immunoassay: North ... , the global multiplex detection immunoassay market is expected to witness ... ... ,      (Logo: ...
(Date:12/6/2016)... 6, 2016  Alopexx Oncology, LLC announced data from ... fusion protein (immunocytokine) composed of interleukin-2 and a CD20-targeting ... on B cells as Rituxan and maintains the activities ... also involved in tumor targeting, engagement of the immune ... results of the study (abstract #95954) were presented at ...
(Date:12/6/2016)... 6, 2016 Homozygous Familial Hypercholesterolemia ... Summary Global Markets Direct,s latest Pharmaceutical ... Hypercholesterolemia (HoFH) – Pipeline Review, H2 2016, ... Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline landscape. ... which is caused due to mutation from ...
Breaking Medicine Technology:
(Date:12/7/2016)... San Fernando Valley, CA (PRWEB) , ... December 07, 2016 , ... ... Sculptra can be used in several ways to restore a more youthful appearance to ... doctors , now offer Sculptra, along with a variety of other treatments, to rejuvenate ...
(Date:12/7/2016)... ... December 07, 2016 , ... ODU, a ... the US market its advanced highly customizable contact technology solutions. , ODU Single ... advanced technologies are ideal for a wide range of applications that require customization ...
(Date:12/7/2016)... ... ... AlignLife clinics nationwide are giving back to their communities by collecting toys during ... wrapped tightly under a Christmas Tree. AlignLife hopes to spread the joy and ... exchange for generous donations, customers will receive a gift in return. Anyone who ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. ... season by donating a portion of proceeds to two local organizations: North Chicago Animal ... Control & Friends is a team of authorized and trained volunteers who support ...
(Date:12/7/2016)... California (PRWEB) , ... December 07, 2016 , ... "ProBrand ... any and all media," said Christina Austin - CEO of Pixel Film Studios. , ... with easy to use drop zones. Editors can select from a variety of flip ...
Breaking Medicine News(10 mins):